Name (Synonyms) | Correlation | |
---|---|---|
drug733 | Deferoxamine Wiki | 0.50 |
drug1978 | Questionnaire Wiki | 0.15 |
Name (Synonyms) | Correlation | |
---|---|---|
D002386 | Cataract NIH | 0.71 |
D011014 | Pneumonia NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000518 | Cataract HPO | 0.71 |
HP:0002090 | Pneumonia HPO | 0.04 |
There are 2 clinical trials
This study project includes a single-arm phase 2 study and a parallel observational cohort study, enrolling patients with COVID-19 pneumonia.
Description: 1-month mortality is defined as the ratio of patients who will alive after 1month from study start out of those registered at baseline
Measure: One-month mortality rate Time: up to 1 monthDescription: IL-6 levels will be assessed using commercial ELISA method.
Measure: Interleukin-6 level Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: Lymphocyte count assessed by routinely used determination of blood count
Measure: Lymphocyte count Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: CRP is assessed by routinely used determination of CRP
Measure: CRP (C-reactive protein) level Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: calculated from arterial blood gas analyses (values from 300 to 100)
Measure: PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: It evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.
Measure: Change of the SOFA (Sequential Organ Failure Assessment) Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: graded according to CTCAE citeria (v5.0)
Measure: Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0 Time: during treatment and up to 30 days after the last treatment doseDescription: Thoracic CT scan or Chest XR
Measure: Radiological response Time: at baseline (optional), after seven days and if clinically indicated (up to 1 month)Description: Days of hospitalization
Measure: Duration of hospitalization Time: from baseline up to patient's discharge (up to 1 month)Description: time to invasive mechanical ventilation (if not previously initiated) calculated from baseline to intubation
Measure: Remission of respiratory symptoms Time: up to 1 monthDescription: time to definitive extubation calculated from intubation (any time occurred) to extubation in days
Measure: Remission of respiratory symptoms Time: up to 1 monthDescription: time to independence from non-invasive mechanical ventilation calculated in days
Measure: Remission of respiratory symptoms Time: up to 1 monthDescription: time to independence from oxygen therapy in days
Measure: Remission of respiratory symptoms Time: up to 1 monthAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)
Measure: the mortality rate Time: 90 day